

This is the **Exhibit A** referred to in the Declaration under  
37 C.F.R. Section 1.132 of ANTONY WILKS BURGESS  
dated June 14, 2006.

January 2006

**TONY BURGESS  
CURRICULUM VITAE**

**INDEX**

	<b>Page No.</b>
<b>1. Personal Details</b>	<b>2</b>
<b>2. University Training</b>	<b>2</b>
<b>3. Positions Held</b>	<b>2</b>
<b>4. Scientific Appointments</b>	<b>3</b>
<b>5. Honours and Awards</b>	<b>4</b>
<b>6. Postgraduate and Undergraduate Teaching Involvement</b>	<b>4</b>
<b>7. Conference Presentations</b>	<b>4</b>
<b>8. Peer Review Involvement</b>	<b>6</b>
<b>9. Organisation of Local, National and International Meetings</b>	<b>6</b>
<b>10. Research Achievements</b>	<b>7</b>
<b>11. Publications</b>	<b>10</b>
<b>12. Patents</b>	<b>34</b>

**CURRICULUM VITAE**

1. **NAME:** Antony Wilks BURGESS

**DATE OF BIRTH:** 13<sup>th</sup> March, 1946

**CITIZENSHIP:** Australian

2. **UNIVERSITY TRAINING:**

1967 B.Sc., University of Melbourne

1969 B.Sc.(Hons) 1st Class, Biochemistry  
University of Melbourne

1972 Ph.D. Protein Chemistry, University of Melbourne

3. **POSITIONS HELD:**

1970-72 Postgraduate Research Scholar  
Wool Sciences, CSIRO - Melbourne

1972-74 Research Fellow, Chemistry Department  
Cornell University

1973-74 Research Fellow, Biophysics Department Weizmann  
Institute, Rehovot, Israel

1975-77 Postdoctoral Research Fellow  
Cancer Research Unit  
The Walter & Eliza Hall Institute of Medical Research,  
Melbourne

1977-79 Senior Research Officer  
Head of Laboratory - Biological Regulators  
The Walter & Eliza Hall Institute of Medical Research,  
Melbourne

1980-Present Director, Melbourne Branch  
Ludwig Institute for Cancer Research

1980-1982 Senior Associate, Department of Surgery  
University of Melbourne

1980-1982	Honorary Principal Research Fellow The Walter & Eliza Hall Institute of Medical Research, Melbourne
1982-1988	Professorial Associate, Department of Surgery University of Melbourne
1988-Present	Professor of Cell Biology, Department of Surgery University of Melbourne

#### 4. SCIENTIFIC APPOINTMENTS

1981-83	Scientific Advisor, Australian Academy of Science, Weizmann Institute Fund
1981-83	Scientific Advisor, Sydney Cancer Research Fund
1985-87	NH&MRC Regional Interviewing Committee
1985-96	Member, Medical & Scientific Committee, Anti Cancer Council of Victoria
1987-92	World Committee Member, Society for Research into Comparative Leukemia Associated Diseases
1988-02	Victor Hurley Fellowship & Keir Fellowship Committees, Royal Melbourne Hospital
1989-90	Chairperson, Planning Committee for Biomolecular Research Institute, Strategic Research Fund Victorian Chair of Anaesthesia Advisory Committee Research Committee, Peter MacCallum Cancer Institute
1990-01	Chairperson, Board of Biomolecular Research Institute
1993-97	Committee for the Tumour Biology Programme, International Union Against Cancer
1993-03	Founder & Member, Centre for Developmental Cancer Therapeutics (CDCT)
1993-98	Member, Organizing Committee, Australian Cancer Network
1994-00	Board Member, International Society of Differentiation
1995-00	Member, National Cancer Advisory Committee
1996-00	Chairperson, Scientific Committee, Victorian Breast Cancer Research Consortium
1996- 04	Management Committee, CRC for Cellular Growth Factors
1997-01	Executive Committee, Australian Society of Biochemistry and Molecular Biology
1998-02	Member, National Committee for Biochemistry, Australian Academy of Science
1998-00	President, Australian Society of Biochemistry & Molecular Biology, Inc.
2000-01	Visiting Professorial Fellow, Institute of Advanced Studies, Hebrew University
2001-02	Member, Scientific Advisory Committee, Bio21
2001-02	Member, Cancer Council of Victoria, Comprehensive Cancer Centre Working Party
2001-02	Member, Austin Research Redevelopment Reference Group
2001-03	Member, Austin Biomedical Alliance Research Committee
2001-present	Member, Scientific Committee, Victorian Breast Cancer Research Consortium
2002-present	Committee Member, Strategy Committee ONJCC

- 2003-2004 Board Director, Cancer Trials Australia
- 2003-present Member, CSIRO Sector Advisory Council
- 2003-present Board Member, Victorian Breast Cancer Research Consortium Inc.
- 2003-present Board Director, Bio21
- 2003-present Committee Member, Ministerial Cancer Taskforce

## 5. HONOURS AND AWARDS

- 1969 CSIRO Postgraduate Scholarship
- 1972 Australian American Education Foundation Travel Grant
- 1975 Queen Elizabeth II Postdoctoral Research Fellowship
- 1981 Gottschalk Medal, Australian Academy of Science
- 1993 Elected Fellow, Australian Academy of Science
- 1995 Amgen Prize
- 1998 Companion of the Order of Australia
- 1998 Elected Fellow, Asia-Pacific International Molecular Biology Network
- 1999 Medical Oncology Group/AMRAD Cancer Achievement Award
- 2003 Centenary Medal
- 2005 Leach Lecture Medal

## 6. POSTGRADUATE AND UNDERGRADUATE TEACHING INVOLVEMENT

- Successful supervision of 25 PhD students from 1980-2002
- Lecture courses to BSc., BScHons and MBBS students
- "Introduction to Bioinformatics Course" for undergraduates 1999-2002, Melbourne
- Gene Technology Access Centre Teachers Lecture Series, WEHI, Melbourne, 2002

## 7. CONFERENCE PRESENTATIONS (1998-2004)

### 1998

- Invited speaker: 17<sup>th</sup> UICC International Cancer Congress, Brazil
- Invited speaker: Kyowa Hakko Kogyo Symposium, Japan
- Invited speaker: ASBMB/ASPP Conference, Adelaide

### 1999

- Invited speaker: Leeds Castle Conference, Melbourne
- Invited speaker: LICR Signalling Meeting, New York, USA
- Invited speaker: MOG Mid-Year Meeting, Hamilton Island, Qld
- Invited speaker: ASBMB Combio 99, Queensland
- Invited speaker: Victor Chang Cardiac Research Institute Seminar, Sydney
- Invited speaker: Beijing Tumour Immunology Conference, China

### 2000

- Invited speaker: International Symposium on Tumor Immunology and Immunotherapy, Beijing
- Invited speaker: International Congress on Differentiation and Molecular Cell Biology, Queensland
- Invited speaker: Institute for Advanced Studies, Hebrew University of Jerusalem, Israel
- Invited speaker: 18<sup>th</sup> International Congress of Biochemistry & Molecular Biology, Birmingham, UK
- Invited speaker: Cornell University, New York, USA
- Invited speaker: Amgen Seminar, California, USA

### 2001

- Invited speaker: Royal Melbourne Hospital Familial Cancer Symposium, Melbourne
- Invited speaker: Yonsei University Protein Network Research Centre, Korea
- Invited speaker: Garvan Institute, Sydney
- Invited speaker: QIMR Scientific Symposium, Brisbane
- Invited speaker: 12<sup>th</sup> World Congress of Neurosurgery, Melbourne
- Invited speaker: Australian Society of Head & Neck Surgery, 2001, Melbourne
- Invited speaker: Australia-Korea Frontiers of Science and Technology and Bioinformatics Workshop, Melbourne University

### 2002

- Invited speaker: Beyond the Human Genome: the pharmaceutical industry in the new Millennium Symposium Melbourne
- Invited speaker: ErbB Symposium, Vanderbilt University, USA
- Invited speaker: Oncology Grand Round Talk, Austin Repatriation & Medical Hospital, Melbourne
- Invited speaker: Gene Technology Access Centre Teachers Lecture Series, WEHI, Melbourne
- Invited speaker: CSIRO Preclinical Forum, Melbourne
- Invited speaker: CRC-CGF Bioinformatics Course 2002, Melbourne
- Invited speaker: AGITG Annual Meeting, Hobart
- Invited speaker: Biophysical Chemistry in Health and Disease, Weizmann Institute of Science, Israel

### 2003

- Invited speaker: Annual Scientific Meeting, Australian New Zealand Breast Cancer Trials Group, Adelaide
- Invited speaker: 2<sup>nd</sup> Annual Symposium on Anti-Signaling Strategies in Human Neoplasia, Chicago, USA
- Invited speaker: Therapeutic Area Training: Bowel Cancer, Clinical Trials Victoria, Melbourne

### 2004

- Invited speaker: New Era for Gene Medicine Symposium, Institute of Medical Science, Tokyo, Japan
- Invited speaker: AACR 95<sup>th</sup> Annual Meeting, Orlando, Florida, USA
- Invited speaker: College of Surgeons Annual Scientific Congress Melbourne, Australia
- Invited speaker: ARI/LICR Joint Seminar Program, Austin Campus, Melbourne, Australia

Invited speaker: WEHI Postgraduate Seminar, WEHI, Melbourne, Australia

Invited speaker: Bioinformatics Lecture, LICR, Melbourne, Australia

Invited speaker: Brain Tumours Seminar, Dept of Surgery, Melbourne University

Invited speaker: HMRI Cancer Conference, Newcastle, Australia

Invited speaker: PNRC International Symposium on Proteomics and Cell Signaling, Yonsei University, Korea

Invited speaker: DHS Translational Research Seminar, Melbourne, Australia

Invited speaker: AH&MRC 2<sup>nd</sup> Congress, Darling Harbour, Sydney, Australia

## 2005

Invited speaker: Ludwig-PNRC Joint Symposium, Yonsei University, Korea

Invited speaker: ComBio2005, Adelaide, Australia

Invited speaker: Boden Research Conference 2005, Sydney, Australia

## **8. PEER REVIEW INVOLVEMENT**

### **Editorial Boards**

1981 – 1983 Experimental Hematology

1985-2001 Bio Essays, Board Member

1989-1990 Experimental Hematology, Board Member

1990- Growth Factors, Editor-in-Chief

1990- Journal of Experimental Therapeutics and Oncology

1998-2002 Journal of Cell Science, Board Member

2001- Encyclopedia of Hormones, Associate Editor,

### **Review Panels**

Australian Research Council Expert Advisory Committee, Centre of Excellence

The Cancer Council (NSW) Fellowship Selection Committee

Scientific Peer Review, Foundation for Research Science & Technology, NZ

Selection Committee for appointment of Chief Health Science & Nutrition, CSIRO

ARC Federation Fellow Advisory Committee

Advisor, National Honours Secretariat Scientific Discipline Involvement

Strategic Advisor: Hanson Centre, Peter MacCallum, Monash University, Victorian Government Department of Innovation

Advisor: Amgen, Biogen, Schering Plough, Kirin

NH&MRC Peer Review Advisory Panel (2006+)

### **Reviewer for journals (average per year)**

~20 articles per year - (J. Biol. Chem., Nature, Science, JACS, Exp. Cell Res., J. Cell Sci., Eur. J. Biochem.)

### **Grant Reviews (average per year)**

1990 to 2000 ~150 per year. 2001 to 2003 ~75 per year

(NH&MRC, Cancer Council of Victoria, ARC, Charities, NIH, NZ Science Council)

## **9. ORGANISATION OF LOCAL, NATIONAL AND INTERNATIONAL MEETINGS**

- 1988-1998 Founder & Member, Organising Committee, Lorne Cancer Conference, Lorne
- 1988-2003 Organizer Cancer Research Australia (CARA) database
- 1988 Organizer, Growth Factors and Cancer Meeting, Keystone
- 1999 Founder & Member of Organizing Committee, Australian Molecular Modelling Workshop (Annual Meeting)
- 2000-01 Member, Organising Committee, 11<sup>th</sup> International Conference on Second Messengers and Phosphoproteins, Melbourne
- 2001 Organiser Couran Cove Asia Pacific Molecular Biology Training Program Conference, Queensland
- 2003 Organising Committee International EGFR Collaboration Meeting, Melbourne

## 10. RESEARCH ACHIEVEMENTS

I am currently the Director of the Ludwig Institute for Cancer Research Melbourne and have held this position since 1980. I also hold the positions of Professor of Cell Biology in the Department of Surgery at the University of Melbourne and an Honorary Principal Research Fellow at The Walter and Eliza Hall Institute of Medical Research.

### 1970-1980

Between 1972 and 1974 I worked as a Research Fellow in the Chemistry Department at Cornell University and the Biophysics Department at the Weizmann Institute, Rehovot, Israel. My research was directed towards developing an understanding of the processes and molecular interactions determining the shapes and folding pathways of peptides and proteins. I helped to develop an algorithm to simulate the atomic forces that occur during peptide and protein folding and which eventually determine the three-dimensional coordinates of the equilibrium conformation (*Momany, F.A. et al [1975] Energy Parameters in Polypeptides 7. Geometric Parameters, Partial Atomic Charges, Nonbonded Interactions, Hydrogen-Bond Interactions, and Intrinsic Torsional Potentials for Naturally Occurring Amino-Acids. Journal of Physical Chemistry 79(22): 2361-2381, CIT: 1,390*). This initial work was on peptides and even smaller molecules and involved an analysis (identification) of the interactions critical for the conformational distribution. I developed a procedure to predict the alpha helical and beta sheet conformation of proteins. A new molecular representation was created to simulate intermolecular interactions more accurately; this representation assisted our understanding of both solid phase and solution conformations for small molecules. I concentrated on the formulation of the protein-folding problem and my work identified both the challenge and difficulties with simulation algorithms for these interactions. These studies were complemented by some experimental collaborations aimed at detecting the earliest events associated with protein unfolding and folding. These collaborations used photolysis to detect rapid changes in the surface of a protein during its folding. My final set of investigations involved the simplification of the force field to allow the calculations to be performed more quickly and thus more comprehensively for proteins and protein-polysaccharide interactions.

In 1975, I took up a Post-Doctoral Research Fellowship with the Cancer Research Unit at the Walter and Eliza Hall Institute of Medical Research in Melbourne. In 1977 I was made a Senior Research Fellow with the Walter and Eliza Hall Institute and in 1980 a Honorary Principal Research Fellow. Whilst there, I became the first person in the world to purify a

hormone which regulated blood cell production, G-CSF. This involved conventional protein chemistry techniques including chromatography (ion exchange, affinity and gel filtration) as well as preparative polyacrylamide gel electrophoresis and isoelectric focussing (*Burgess AW, et al [1977] Purification and properties of colony-stimulating factor from mouse-conditioned medium. Journal of Biological Chem 252:1998-2003, CIT: 530*). Together with Professor Donald Metcalf, I was involved in the discovery, characterization and isolation of G-CSF and several other new blood cell hormones (GM-CSF and multi-CSF, also called interleukin-3) (*Metcalf D, et al. [1978] Production of hemopoietic stimulating factors by pokeweed-mitogen-stimulated spleen cells. Transplantation Proceeding, 10:91-94; Nicola NA, et al. [1978] Preparation of colony stimulating factors from human placental conditioned medium. Leukaemia Research 2:313-322; Burgess A W, et al. [1980] Granulocytemacrophage-, megakaryocyte-, eosinophil- and erythroid-colony stimulating factors produced by mouse spleen cells. Biochemistry Journal, 185:301-314*). This work required the establishment of growth factor production systems and purification and characterization of minute amounts of protein.

### 1980-1990

In 1980 I moved to my current position as Director of the Ludwig Institute for Cancer Research. My early work at the Ludwig Institute (1980-1985) was directed towards the development of uses for the blood cell hormones GM-CSF and G-CSF (*Burgess AW and Metcalf D [1980] Characterization of a serum factor stimulating the differentiation of myelomonocytic leukemic cells. International Journal of Cancer, 26:647-654, CIT: 119*). At the same time I was involved in the initiation of a research program on colon cancer which focused on the biochemistry and biology of the epidermal growth factor family of proteins (*Burgess AW et al [1982] Two forms of murine epidermal growth factor; Rapid separation by using reversed phase HPLC. Proceedings of the National Academy of Sciences USA 79:5753-5757*). The availability of bacterial protein expression systems opened up new opportunities for the protein chemistry of growth factors. I co-ordinated the amino acid sequencing of GM-CSF (*Sparrow LG, et al [1985] Purification and partial amino acid sequence of asialo murine granulocyte-macrophage colony stimulating factor. Proceedings of the National Academy of Sciences USA 82:292-296*) which allowed the use of molecular biology techniques to help define the first recombinant clones of this growth factor (*Gough NM, et al [1984] Molecular cloning of cDNA encoding a murine haemopoietic growth regulator, granulocyte-macrophage colony stimulating factor. Nature 309:763-767*). The initial discovery and purification of GM-CSF led collaborators to produce recombinant human GM-CSF (*Metcalf D, et al [1986] In vitro actions on hemopoietic cells of recombinant murine GM-CSF purified after production in E. coli.. Comparison with purified native GM-CSF Journal of Cell Physiology 128:421-431*) for use in clinical testing.

The isolation of human GM-CSF from bacterial pellets led to new challenges and problems in protein extraction and folding, as well as high performance reversed phase chromatography (*Burgess AW, et al [1983] Murine epidermal growth factor. Heterogeneity on high resolution ion-exchange chromatography. EMBO Journal 2:2065-2069; Burgess AW, et al [1985] Purification of two forms of colony stimulating factor from mouse L-cell conditioned medium. Journal of Biological Chemistry 260: 16004-16011; Simpson RJ, [1985] Rat epidermal growth factor. Complete amino acid sequence: Homology with the corresponding murine and human proteins but truncated at both ends. European Journal of Biochemistry 153:629-637*). The initial clinical use of human GM-CSF revealed that this growth factor had a short

half-life in vivo (Cebon J, et al [1988] *Pharmacokinetics of human granulocyte-macrophage colony stimulating factor (hGM-CSF) using a sensitive immunoassay. Blood* 72:1340-1347). I helped to recognize the clinical potential of GM-CSF and established a clinical research team to develop both GM-CSF and G-CSF as therapeutic agents (Morstyn G, et al [1987] *Clinical potential of haemopoietic growth factors (colony stimulating factors) In: Pharmacology, W Rand and C Raper (Eds.) pp. 585-588; Lieschke, GJ, Burgess, A W (1992) Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. N Eng J Med* 327:28-35).

In the late 1980's, I identified the first receptor for a blood cell growth factor (Walker F and Burgess AW [1985] *Specific binding of radioiodinated granulocyte macrophage colony stimulating factor to hemopoietic cells. EMBO Journal* 4:933-939) and discovered important interactions between the receptors for the blood cell growth factors. This work was reported in 1985 in (Walker F, et al [1985] *Hierarchical down-modulation of hemopoietic growth factor receptors. Cell* 43:269-276, CIT 316).

I was involved in the establishment of the three-dimensional structure of EGF in conjunction with colleagues at Cornell University (Montelione GT, et al [1986] *Identification of two anti-parallel  $\beta$ -sheet conformations in the solution structure of murine epidermal growth factor by proton magnetic resonance. 'Proceedings of the National Academy of Sciences USA* 83:8594-8598). The studies we conducted in the mid-eighties required EGF of the highest purity. Most of our studies had involved the use of native EGF extracted from mouse salivary glands, but the amounts we could produce and the structure of the molecules prevented us from initiating high resolution structural studies. This lead us to investigate recombinant procedures for synthesizing larger amounts of EGF (and its derivatives) as well as a related mitogen, transforming growth factor TGF $\alpha$  and the EGF receptor itself. We also investigated the physiology of epidermal growth factor members in the gastrointestinal tract (Malden, L. T., et al [1989] *Expression of Transforming Growth Factor-Alpha Messenger-Rna in the Normal and Neoplastic Gastrointestinal-Tract. International Journal of Cancer*, 43(3): 380-384, CIT: 130).

**1990-2003** This phase of my work was directed towards colon cancer biology and the structure, function and signalling from the EGF receptor in normal and transformed cells.

We identified some of the growth factors and receptors which influence the production and differentiation of both normal and neoplastic cells. It was clear that fibroblast growth factors could induce the proliferation of both colonic cell lines and normal cells. My group undertook to determine the autocrine "growth factors" which were required for the proliferation of colonic carcinoma cells. As expected, transforming growth factor  $\alpha$  (TGF- $\alpha$ ) was a major regulator, but another autocrine factor was required for colonic cells to respond to TGF- $\alpha$ . We isolated this other protein and with mass-spectrometric identification, we identified laminin-10 as an essential autocrine factor required for colon carcinoma cells to proliferate *in vitro*.

During our characterization of colonic cell membranes, we had the opportunity to identify a specific intestinal cell surface protein called A33. This protein is a very useful marker for detecting metastatic colonic cells and the promoter sequences have been useful for developing colonic cell expression systems. Most recently we have concentrated on characterizing the

proteins associated with colon cancer: apc, ras and the EGF receptor system. We have determined that truncation of APC and oncogenic activation of ras is sufficient to produce colon cancer cells. We have developed several systems to study the biochemistry and biology of APC (see Research Plan) and will combine the knowledge gained from this research with our EGF receptor inhibitor antagonist program.

Together with my colleague Francesca Walker we identified an unusual super-agonist of EGF (a Val mutant) which uncovered an important aspect of mitogenic signalling, namely the degradation of the ligand receptor complex. My group has continued to contribute to the biochemistry and biology of the EGF/EGF receptor family, in particular to improving our understanding of the mechanisms of trans-modulation and the formation of the high-affinity state. We were one of the first groups to prove that autocrine TGF- $\alpha$  was responsible for the proliferation and survival of colon carcinoma cells.

Although we were able to improve our understanding of the 3-D structure of EGF our initial attempts to crystallize the EGF receptor were most frustrating. We focussed on the signalling events, the mechanism of activation of the EGF receptor. In the early 1990's TGF- $\alpha$  was presumed to be the mitogenic stimulus for the steady state production of epidermal and mucosal tissues such as the colon. I was involved in the characterization of a strain of knock-out mice, TGF- $\alpha$   $-/-$ , and the waved-2 mouse which we determined had a naturally occurring defective variant of the EGF receptor kinase. These two mice changed our views of EGF receptor physiology and pathology, clearly the interactions between other EGF ligands and the other members of the EGF receptor family were able to compensate for many of the processes controlled by the EGF receptor.

Our signalling studies have directed attention to the multiple pathways stimulated by the EGF receptor. Combinations of signalling events in different cell types leads to distinct biological outcomes. The interaction between the EGF receptor and the integrin signalling systems is an area of major importance for the survival and progression of colon tumour cells. Now that we are moving towards a more comprehensive understanding of the individual biochemical lesions involved in carcinogenesis, it will be possible to suppress the proliferation of tumour cells with inhibitors of signalling pathways. Indeed with the appropriate combinations of inhibitors, it may even be possible to induce apoptosis in tumour cells.

It is an exciting phase of my research career to be contributing to the development of new anti-cancer therapeutics. Our most recent collaborative work with Colin Ward and Tom Garrett, the solving of the 3D structure for the EGF receptor extracellular domain:TGF- $\alpha$  complex and erbB2 has been a highlight (*Garrett, T.P. et al. [2002] Crystal Structure of a Truncated Epidermal Growth Factor Receptor Extravellular Domain Bound to Transforming Growth Factor  $\alpha$ . Cell 110:763-773 & Garrett, T.P.J., et al [2003] The first 3 domains of ErbB2 ectodomain adopt a pseudo-active form of the receptor. Molecular Cell 11:495-505*). We have been involved with this collaboration for almost a decade and to see the structure, understand the ramifications that the structure has for the biology of the receptor and the potential for direct antagonist design are most exciting. We are using the opportunity to develop an opportunity for improving the therapy of colon cancer and gliomas.

In total I have authored or co-authored about 250 scientific papers in refereed journal. The majority of these have been in the field of cell biology and protein chemistry. I have also held a large number of office-bearing positions in my field of scientific expertise and in organizing expert teams on behalf of the biochemical community. It has been particularly exciting to see the successful development of several conferences and organisations I helped to form.

## 11. PUBLICATIONS:

1. BURGESS, A.W. (1972) Protein structure and enzyme mechanisms: Can quantum theory help? *Search*, 3:74-76.
2. BURGESS, A.W., Momany, F.A. and Scheraga, H.A. (1973). Conformational analysis of thyrotropin releasing factor. *Proc. Natl. Acad. Sci.*, 70:1456-1460.
3. BURGESS, A.W. and Scheraga, H.A. (1973) Stable conformations of dipeptides. *Biopolymers*, 12:2177-2183.
4. BURGESS, A.W. and Leach, S.J. (1973) An obligatory  $\alpha$ -helical amino acid residue. *Biopolymers*, 12:2599-2605.
5. Scheraga, H.A., Lewis, P.N., Momany, F.A., Von Dreel, P.H., BURGESS, A.W. and Howard, J.C. (1973) Hairpin bends in oligopeptides and proteins. *Fed. Proc.*, 32:495.
6. BURGESS, A.W., and Leach, S.J. (1973) Conformational studies on alamethicin. *Biopolymers*, 12:2691-2712.
7. BURGESS, A.W., Ponnuswamy, P.K. and Scheraga, H.A. (1974) Analysis of conformations of amino acid residues and prediction of backbone topography in proteins. *Israel J. Chem.*, 12:239-286.
8. BURGESS, A.W., Paterson, Y. and Leach, S.J. Effects of methylation on the energetically preferred helical conformations of polypeptides. In: *Peptides, Polypeptides and Proteins*, E.R. Blout et al. (eds.), Academic Press, 1974, pp.79-88.
9. Shipman, L.L., BURGESS, A.W. and Scheraga, H.A. (1975) A new approach to empirical intermolecular and conformational potential energy functions. I. Description of model and derivation of parameters. *Proc. Natl. Acad. Sci.*, 72:543-547.
10. BURGESS, A.W., Shipman, L.L. and Scheraga, H.A. (1975) A new approach to empirical intermolecular and conformational potential energy functions. II. Applications to crystal packing, rotational barriers, and conformational analysis. *Proc. Natl. Acad. Sci.*, 72:854-858.
11. BURGESS, A.W. and Scheraga, H.A. (1975) Assessment of some problems associated with prediction of the three-dimensional structure of a protein from its amino acid sequence. *Proc. Natl. Acad. Sci.*, 72:1221-1225.

12. BURGESS, A.W. and Scheraga, H.A. (1975) A hypothesis for the pathway of the thermally-induced unfolding of bovine pancreatic ribonuclease. *J. Theor. Biol.*, 54:403-420.
13. BURGESS, A.W., Paterson, Y. and Leach, S.J. (1975) The random coil dimensions of methylated polypeptides. *J. Polymer. Sci.*, 49:75-83.
14. BURGESS, A.W., Weinstein, L.I., Gabel, D. and Scheraga, H.A. (1975) Immobilized carboxypeptidase A as a probe for studying the thermally induced unfolding of bovine pancreatic ribonuclease. *Biochem.*, 14:197-200.
15. BURGESS, A.W., Momany, F.A. and Scheraga, H.A. (1975) On the structure of thyrotropin releasing factor. *Biopolymers*, 14:2645-2647.
16. Momany, F.A., McGuire, R.F., BURGESS, A.W. and Scheraga, H.A. (1975) Energy parameters in polypeptides. VII. Geometric parameters, partial atomic charges, non-bonded interactions, hydrogen bonded interactions, and intrinsic torsional potentials for the naturally occurring amino acids. *J. Phys. Chem.*, 79:2361-2381.
17. BURGESS, A.W., Shipman, L.L., Nemanoff, R.A. and Scheraga, H.A. (1976) A new approach to empirical intermolecular and conformational potential energy functions. III. Application of EPEN to the conformation analysis of 1,2-disubstituted ethanes. *J. Amer. Chem. Soc.*, 98:23-29.
18. Shipman, L.L., BURGESS, A.W. and Scheraga, H.A. (1976) Lattice energies and heats of sublimation of O K for n-pentane, n-hexane, n-octane, and ammonia. *J. Phys. Chem.*, 80:52-54.
19. Pincus, M.R., BURGESS, A.W. and Scheraga, H.A. (1976) Conformational energy calculations of enzyme-substrate complexes of lysozyme. I. Energy minimization of monosaccharide and oligosaccharide inhibitors and substrates of lysozyme. *Biopolymers*, 15:2485-2521.
20. Matheson, R.R., Jr., Van Wart, H.E., BURGESS, A.W., Weinstein, L.I. and Scheraga, H.A. (1977) Study of protein topography with flash photolytically generated nonspecific surface-labeling reagents: Surface labeling of ribonuclease A. *Biochem.*, 16:396-403.
21. BURGESS, A.W. and Metcalf, D. (1977) Serum half-life and organ distribution of radiolabeled colony stimulating factor in mice. *Exp. Hematol.*, 5:456-464.
22. BURGESS, A.W., Wilson, E.M.A. and Metcalf, D. (1977) Stimulation by human placental conditioned medium of hemopoietic colony formation by human marrow cells. *Blood*, 49:573-583.
23. BURGESS, A.W., Camakaris, J. and Metcalf, D. (1977) Purification and properties of colony-stimulating factor from mouse lung-conditioned medium. *J. Biol. Chem.*, 252:1998-2003.

24. BURGESS, A.W. and Metcalf, D. Colony-stimulating factor and the differentiation of granulocytes and macrophages. In: "Experimental Hematology Today", S.J. Baum and G.D. Ledney (eds.), Springer-Verlag, N.Y. pp. 135-146, 1977.
25. BURGESS, A.W. and Metcalf, D. (1977) The effect of colony stimulating factor on the synthesis of ribonucleic acid by mouse bone marrow cells in vitro. *J. Cell. Physiol.*, 90:471-484.
26. Claesson, M.H., Whittingham, S., Rodger, M.B. and BURGESS, A.W. (1977) Colony growth of human T lymphocytes in agar: Effect of a soluble factor from adherent cells. *Eur. J. Immunol.*, 7:608-612.
27. Moore, M.A.S., BURGESS, A.W., Metcalf, D., McCulloch, E.A., Robinson, W.A., Dicke, K.A., Chervenick, P.A., Bull, J.M., Wu, A.M., Stanley, E.R., Goldman, J. and Testa, N. (1977) Report of a workshop on standardization of selective cultures for normal and leukaemic cells. *Br. J. Cancer*, 35:500-508.
28. Metcalf, D., Russell, S. and BURGESS, A.W. (1978) Production of hemopoietic stimulating factors by pokeweed-mitogen-stimulated spleen cells. *Transplantation Proceedings*, 10:91-94.
29. Swenson, M.K., BURGESS, A.W. and Scheraga, H.A. Conformational analysis of polypeptides: Application to homologous proteins. In: "Frontiers in Physicochemical Biology", B. Pullman (ed.), Academic Press, N.Y., 1978, pp. 115-142.
30. BURGESS, A.W., Metcalf, D. and Russell, S. Regulation of hematopoietic differentiation and proliferation by colony-stimulating factors. In: "Differentiation of Normal and Neoplastic Hematopoietic Cells", B. Clarkson (ed.), Cold Spring Harbor Laboratory, N.Y., pp. 339-357, 1978.
31. Johnson, G.R. and BURGESS, A.W. (1978) Molecular and biological properties of a macrophage colony-stimulating factor from mouse yolk sacs. *J. Cell. Biol.*, 77:35-47.
32. Dunfield, L.G., BURGESS, A.W. and Scheraga, H.A. (1978) Energy parameters in polypeptides. 8. Empirical potential energy algorithms for the conformational analysis of large molecules. *J. Phys. Chem.*, 82:2609-2616.
33. BURGESS, A.W., Metcalf, D., Nicola, N.A. and Russell, S.H.M. (1978) Purification and characterization of cell specific colony stimulating factors. In: "Hematopoietic Cell Differentiation", D.W. Golde et al. (eds.), Academic Press, New York, 10:399-416.
34. BURGESS, A.W., Metcalf, D. and Watt, S.M. (1978) Regulation of hemopoietic cell differentiation and proliferation. *J. Supramolec. Struct.*, 8:489-500.
35. Nicola, N.A., BURGESS, A.W., Metcalf, D. and Battye, F.L.. (1978) Separation of mouse bone marrow cells using wheat germ agglutinin affinity chromatography. *Aust. J. Exp. Biol. Med. Sci.*, 56:663-679.

36. Nicola, N.A., Metcalf, D., Johnson, G.R. and BURGESS, A.W. (1978) Preparation of colony stimulating factors from human placental conditioned medium. *Leukaemia Res.*, 2:313-322.
37. Tew, J.G., Mandel, T.E. and BURGESS, A.W. (1979) Retention of intact HSA for prolonged periods in the popliteal lymph nodes of specifically immunized mice. *Cell Immunol.*, 45:207-212.
38. Nicola, N.A., BURGESS, A.W. and Metcalf, D. (1979). Similar molecular properties of granulocyte-macrophage colony-stimulating factors produced by different mouse organs in vitro and in vivo. *J. Biol. Chem.*, 254:5290-5299.
39. Handman, E. and BURGESS, A.W. (1979) Stimulation by granulocyte-macrophage colony-stimulating factor of *Leishmania tropica* killing by macrophages. *J. Immunol.*, 122:1134-1137.
40. Nicola, N.A., Metcalf, D., Johnson, G.R. and BURGESS, A.W. (1979) Separation of functionally distinct human granulocyte-macrophage colony-stimulating factors. *Blood*, 54:614-627.
41. Potter, T.A., Watt, S.M., BURGESS, A.W. and McKenzie, I.F.C. (1979) Characterization of surface alloantigens of murine neutrophils. *Immunogenetics*, 8:461-473.
42. Watt, S.M., BURGESS, A.W. and Metcalf, D. (1979) Isolation and surface labeling of murine polymorphonuclear neutrophils. *J. Cell. Physiol.*, 100:1-22.
43. Howard, M., BURGESS, A.W., McPhee, D. and Metcalf, D. (1979) T-cell hybridoma secreting hemopoietic regulatory molecules: Granulocyte-macrophage and eosinophil colony-stimulating factors. *Cell*, 18:993-999.
44. BURGESS, A.W. and Metcalf, D. Control of blood cell formation. *Scientific American*.
45. BURGESS, A.W. Metcalf, D., Russell, S.H.M. and Nicola, N.A. (1980) Granulocyte/macrophage-, megakaryocyte-, eosinophil- and erythroid- colony-stimulating factors produced by mouse spleen cells. *Biochem. J.*, 185:301-314.
46. BURGESS, A.W., Cruise, K.M., Mitchell, G.F. and Watt, S.M. (1980) Preparation and surface labeling of murine eosinophils. *Exp. Hematol.*, 8:108-119.
47. Staber, F.G. and BURGESS, A.W. (1980) Serum of lipopolysaccharide-treated mice contains two types of colony-stimulating factor, separable by affinity chromatography. *J. Cell. Physiol.*, 102:1-10.

48. Metcalf, D., Johnson, G.R. and BURGESS, A.W. (1980) Direct stimulation by purified GM-CSF of the proliferation of multipotential and erythroid precursor cells. *Blood*, 55:138-147.
49. Nicola, N.A., BURGESS, A.W., Staber, F.G., Johnson, G.R., Metcalf, D. and Battye, F. (1980) Differential expression of lectin receptors during hemopoietic differentiation: Enrichment for granulocyte-macrophage progenitor cells. *J. Cell. Physiol.*, 103:217-237.
50. Williams, N. and BURGESS, A.W. (1980) The effect of mouse lung granulocyte-macrophage colony-stimulating factor and other colony-stimulating activities on the proliferation and differentiation of murine bone marrow cells in long-term cultures. *J. Cell. Physiol.*, 102:287-295.
51. Metcalf, D., BURGESS, A.W. and Johnson, G.R. Stimulation of multipotential and erythroid precursor cells by GM-CSF. In: "Experimental Hematology Today", S.J. Baum (ed.), Springer-Verlag, 1980, pp.3-12.
52. BURGESS, A.W. and Metcalf, D. (1980) Characterization of a serum factor stimulating the differentiation of myelomonocytic leukemic cells. *Int. J. Cancer*, 26:647-654.
53. Watt, S.M., and BURGESS, A.W., Metcalf, D. and Battye, F.L. (1980) Isolation of mouse bone marrow neutrophils by light scatter and autofluorescence. *J. Histochem. Cytochem.*, 28:934-946.
54. Hamilton, J.A., Stanley, E.R., BURGESS, A.W. and Shadduck, R.K. (1980) Stimulation of macrophage plasminogen activator activity by colony-stimulating factor. *J. Cell. Physiol.*, 103:435-445.
55. BURGESS, A.W. and Metcalf, D. (1980) The nature and action of granulocyte-macrophage colony stimulating factors. *Blood*, 56:947-958.
56. Watt, S.M. and BURGESS, A.W. (1981) High-resolution two-dimensional electrophoretic analysis of acidic, basic and surface proteins of mouse neutrophils. *Biochem. Biophys. Acta*, 640:583-594.
57. Morstyn, G., Metcalf, D., BURGESS, A.W. and Fabre, J.W. (1981) Surface antigens on normal and leukaemic human cells detected by monoclonal antibodies. *Scand. J. Haematol.*, 26:19-30.
58. Axelrad, A., BURGESS, A.W., Iscove, N. and Wagemaker, G. (1981) Culture of hematopoietic cells: Workshop report. *Control of Cellular Division and Development*, Part B:421-425.
59. Nicola, N.A., Metcalf, D., Von Melchner, H. and BURGESS, A.W. (1981) Isolation of murine fetal hemopoietic progenitor cells and selective fractionation of various erythroid precursors. *Blood*, 58:376-386.

60. BURGESS, A.W., Bartlett, P.F., Metcalf, D., Nicola, N.A., Clark-Lewis, I. and Shradler, J.W. (1981) Granulocyte-macrophage colony-stimulating factor produced by an inducible murine T-cell hybridoma: Molecular properties and cellular specificity. *Exp. Hematol.*, 9:893-903.
61. BURGESS, A.W. (1982) Prebiotic Evolution: Conformational perspectives. *J. Theor. Biol.*, 96:21-38.
62. BURGESS, A.W., Knesel, J., Sparrow, L.G., Nicola, N.A. and Nice, E.C. (1982) Two forms of murine epidermal growth factor: Rapid separation by using reverse-phase HPLC. *Proc. Natl. Acad. Sci.*, 79:5753-5757.
63. Cooper, P.C., Metcalf, D. and BURGESS, A.W. (1982). Biochemical and functional characterization of mature progeny purified from a myelomonocytic leukemia cell line. *Leukemia Research*, 6:313-327.
64. Baldwin, G.S., BURGESS, A.W. and Kemp, B.E. (1982) Phosphorylation of a synthetic gastrin peptide by the tyrosine kinase of A431 cell membranes. *Biochem. Biophys. Res. Commun.*, 109:656-663.
65. Metcalf, D. and BURGESS, A.W. (1982) Clonal analysis of progenitor cell commitment to granulocyte or macrophage production. *J. Cell. Physiol.*, 111:275-283.
66. BURGESS, A.W., Nicola, N.A., Johnson, G.R. and Nice, E.C. (1982) Colony-forming cell proliferation: A rapid and sensitive assay system for murine granulocyte and macrophage colony-stimulating factors. *Blood*, 60:1219-1223.
67. Cooper, P.C. and BURGESS, A.W. (1982) Simultaneous detection of <sup>35</sup>S and <sup>32</sup>P-labeled proteins on electrophoretic gels. *Anal. Biochem.*, 126:301-305.
68. BURGESS, A.W. and Nicola, N.A. (1983) Effect of 12-O-tetradecanoylphorbol-13-acetate (TPA) on the proliferation of granulocyte-macrophage colony-forming cells. *Blood*, 61:575-579.
69. Lopez, A.F., Nicola, N.A., BURGESS, A.W., Metcalf, D., Battye, F.L., Sewell, W.A. and Vadas, M.A. (1983) Activation of granulocyte cytotoxic function by purified mouse colony-stimulating factors. *J. Immunol.*, 131:2983-2988.
70. BURGESS, A.W., Cooper, P.C., Stanley, I.J. and Nicola, N.A. (1983) Effect of colony-stimulating factors on the proteins synthesized by normal and leukemia myeloid progenitor cells. In: *Modern Trends in Human Leukemia v. New Results in Clinical and Biological Research Including Pediatric Oncology*. R. Neth et al. (eds.), Springer-Verlag (Berlin), pp. 338-344.
71. BURGESS, A.W., Lloyd, C.J. and Nice, E.C. (1983) Murine epidermal growth factor: Heterogeneity on high resolution ion-exchange chromatography. *EMBO J.*, 2:2065-2069.

72. Stanley, I.J. and BURGESS, A.W. (1983) GM-CSF stimulates the synthesis of membrane and nuclear proteins in murine neutrophils. *J. Cell. Biochem.*, 23:241-258.
73. BURGESS, A.W. and Nicola, N.A. (1983) *Growth Factors and Stem Cells*. Academic Press (Sydney).
74. BURGESS, A.W. (1984) Growth factors and hemopoietic cell differentiation. *Advances in Cell Culture III*, Academic Press, pp. 231-258.
75. Staber, F.G., BURGESS, A.W., Nicola, N.A. and Metcalf, D. (1984) Biological and biochemical properties of a serum factor that stimulates splenic hemopoiesis in mice. *Exp. Hematol.*, 12:107-113.
76. BURGESS, A.W. (1984) *Cancer: The Secrets Fall*. "Biology in Action" No. 11, published by the Australian Academy of Science.
77. Nice, E.C., Lloyd, C.J. and BURGESS, A.W. (1984) The role of short microbore HPLC columns for protein separation and trace enrichment. *J. Chromatog.*, 296:153-170.
78. BURGESS, A.W. (1984) The complex mediators of cell growth and differentiation. *Immunol. Today*, 5:155-158.
79. Gough, N.M., Gough, J., Metcalf, D., Kelso, A., Grail, D., Nicola, N.A., BURGESS, A.W. and Dunn, A.R. (1984) Molecular cloning of cDNA encoding a murine haemopoietic growth regulator, granulocyte-macrophage colony stimulating factor. *Nature*, 309:763-767.
80. Cooper, P.C. and BURGESS, A.W. (1984) Electrophoretic analysis of the cytoplasmic and nuclear protein changes after induction of differentiation in WEHI-3B myelomonocytic leukemia cells. *J. Cell. Biochem.*, 25:161-182.
81. Cooper, P.C. and BURGESS, A.W. (1985) Biosynthetic labeling with <sup>32</sup>P: Radiation damage to mammalian cells. *Anal. Biochem.*, 144:329-335.
82. BURGESS, A.W. (1985) Hematopoietic growth factors. In: *Proceedings of the 37th Annual Symposium on Cancer Research "Mediators in Cell Growth and Differentiation"*. Raven Press, pp. 159-169.
83. BURGESS, A.W. (1985) Growth factors and cancer. *Aust. N.Z. J. Surg.*, 55:105-110.
84. BURGESS, A.W. (1985) Growth factors and oncogenes. *Immunol. Today*, 6:107-112.
85. Sparrow, L.G., Metcalf, D., Hunkapiller, M.W., Hood, L.E. and BURGESS, A.W. (1985) Purification and partial amino acid sequence of asialo murine granulocyte-macrophage colony stimulating factor. *PNAS*, 82:292-296.

86. Dunn, A.R., Metcalf, D., Stanley, E., Grail, D., King, J., Nice, E.C., BURGESS, A.W. and Gough, N.M. (1985) Biological characterization of regulators encoded by cloned hemopoietic growth factor gene sequences. In: *Cancer Cells 3*, Cold Spring Harbor, pp.227-233.
87. BURGESS, A.W. and Nice, E.C. (1985) Purification of murine granulocyte-macrophage colony-stimulating factor. *Methods Enzymol.*, 116:588-600.
88. Cook, W.D., Metcalf, D., Nicola, N.A., Walker, F. and BURGESS, A.W. (1985) Transformation of A-MuLV of a factor-dependent myeloid cell line without evidence for factor production. *Cell*, 41:677-683.
89. Walker, F. and BURGESS, A.W. (1985) Specific binding of radioiodinated granulocyte macrophage colony stimulating factor to hemopoietic cells. *EMBO J.*, 4:933-939.
90. BURGESS, A.W., Metcalf, D., Kozka, I.J., Simpson, R.J., Vairo, G., Hamilton, J.A. and Nice, E.C. (1985) Purification of two forms of colony stimulating factor from mouse L-cell conditioned medium. *J. Biol. Chem.*, 260:16004-16011.
91. Walker, F., Nicola, N.A., Metcalf, D. and BURGESS, A.W. (1985) Hierarchical down-modulation of hemopoietic growth factor receptors. *Cell*, 43:269-276.
92. BURGESS, A.W. (1985) Haemopoietic growth factors - structure and receptor interactions. In *"Growth Factors in Biology and Medicine"*, CIBA Foundation Symposium, 116:148-168.
93. Simpson, R.J., Smith, J.A., Moritz, R.L., O'Hare, M.J., Rudland, P.S., Morrison, J.R., Lloyd, C.J., Grego, B., BURGESS, A.W. and Nice, E.C. (1985) Rat epidermal growth factor. Complete amino acid sequence: Homology with the corresponding murine and human proteins but truncated at both ends. *Eur. J. Biochem.*, 153:629-637.
94. BURGESS, A.W., Metcalf, D., Sparrow, L.G. and Nice, E.C. (1986) Granulocyte-macrophage colony stimulating factor from mouse lung conditioned medium: Purification of multiple forms and radioiodination. *Biochem. J.*, 235:805-814.
95. Nice, E.C., Smith, J.A., Moritz, R.L., O'Hare, M.J., Rudland, P.S., Morrison, J.R., Lloyd, C.J., Grego, B., BURGESS, A.W. and Simpson, R.J. (1986) Rat epidermal growth factor. Complete amino acid sequence: Isolation of forms truncated at both ends with full in vitro biological activity. In: *Modern Methods in Protein Chemistry* (J. L'Italien, ed.) Plenum Press, New York, In press.
96. Gardner, I.D., Whitehead, R.H. and BURGESS, A.W. (1986) Production and characterization of monoclonal antibodies reactive with subsets of epidermal cells. *Pathology*, 18:313-320.
97. BURGESS, A.W. (1986) Growth factors, receptors and cancer. *BioEssays*, 5:15-18.

98. Walker, F. and BURGESS, A.W. (1987) Internalization and recycling of the granulocyte-macrophage colony stimulating factor (GM-CSF) receptor on a murine myelomonocytic leukemia. *J. Cell. Physiol.*, 130:255-261.
99. Chatelier, R.C., Ashcroft, R.G., Lloyd, C.J., Nice, E.C., Whitehead, R.H., Sawyer, W.H. and BURGESS, A.W. (1986) Binding of fluoresceinated epidermal growth factor to A431 cell sub-populations studied using a model-independent analysis of flow cytometric fluorescence data. *EMBO J.*, 5:1181-1186.
100. BURGESS, A.W. (1986) The control of blood cell production. *Immunology Today*, 7:351-352.
101. Metcalf, D., BURGESS, A.W., Johnson, G.R., Nicola, N.A., Nice, E.C., DeLamarter, J., Thatcher, D.R. and Mermod, J.-J. (1986) In vitro actions on hemopoietic cells of recombinant murine GM-CSF purified after production in *E. coli*: Comparison with purified native GM-CSF. *J. Cell. Physiol.*, 128:421-431.
102. Montelione, G.T., Wüthrich, K., Nice, E.C., BURGESS, A.W. and Scheraga H.A. (1986) Identification of two anti-parallel  $\beta$ -sheet conformations in the solution structure of murine epidermal growth factor by proton magnetic resonance. *Proc. Natl. Acad. Sci. USA*, 83:8594-8598.
103. Gough, N.M. and BURGESS, A.W. (1987) The genes for granulocyte-macrophage colony stimulating factor and multi-colony stimulating factor (IL-3). In: *Oncogenes, Genes and Growth Factors* (G. Guroff, ed.), John Wiley & Sons, NY, pp.165-197.
104. BURGESS, A.W., Begley, C.G., Johnson, G.R., Lopez, A.F., Williamson, D.J., Mermod, J.J., Simpson, R.J., Schmidt, A. and DeLamarter, J.P. (1987) Purification and properties of bacterially synthesized human GM-CSF. *Blood*, 69:43-51.
105. BURGESS, A.W. (1987) Growth factors and their receptors: Specific Roles in development. *BioEssays*, 6:79-81.
106. Scanlon D.B., Eefting M.A., Lloyd C.J., BURGESS A.W. and Simpson R.J. (1987) Synthesis of biologically-active human transforming growth factor- by fluorenyl-methoxycarbonyl solid phase peptide chemistry. *J. Chem. Soc. Chem. Commun.*, 1:516-518.
107. BURGESS, A.W. and Walker, F. (1987) Epithelial growth factors. In: *Integration and Control of Metabolic Processes: Pure and Applied Aspects*. (O.L. Kon, ed.) ICSU Press, Cambridge, pp83-94.
108. Montelione, G.T., Wüthrich, K., Nice, E.C., BURGESS, A.W. and Scheraga, H.A. (1987) Solution structure of murine epidermal growth factor: Determination of the polypeptide backbone chain-fold by nuclear magnetic resonance and distance geometry. *Proc. Natl. Acad. Sci.*, 84:5226-5230.

109. Simpson, R.J., Moritz, R.L., Lloyd, C.J., Fabri, L.J., Nice, E.C., Rubira, M.R. and BURGESS, A.W. (1987) Primary structure of ovine pituitary basic fibroblast growth factor. *FEBS Letters*, 224:128-132.
110. Morstyn, G., Campbell, L., Cebon, J., BURGESS, A.W. and Fox, R. (1987) Clinical potential of haemopoietic growth factors (colony stimulating factors). In: *Pharmacology*, M.J. Rand and C. Raper (eds). pp.585-588.
111. Malden, T.L., Novak, U., Kaye, A.H. and BURGESS, A.W. (1988) Selective amplification of the cytoplasmic domain of the epidermal growth factor receptor gene in glioblastoma multiforme. *Cancer Research*, 48:2711-2714.
112. BURGESS, A.W. (1988) Int-1 and Int-2: Oncogenic proteins, mitogens and morphogens? *BioEssays*, 8:40-42.
113. BURGESS, A.W. (1998) Growth Factors: The Beginnings. *Growth Factors*, 1:1-6.
114. BURGESS, A.W., Lloyd, C.J., Smith, S., Stanley, E., Walker, F., Fabri, L., Simpson, R.J., and Nice, E.C. (1988) Murine epidermal growth factor: Structure and function. *Biochemistry*, 27:4977-4985.
115. Walker, F. and BURGESS, A.W. (1988) Transmodulation of the epidermal growth factor receptor in permeabilized 3T3 cells. *Biochem. J.*, 256:109-115.
116. BURGESS, A.W. (1988) Cell surface heparan sulphate implicated in haemopoietic growth factor signalling. *Immunology Today*, 9:267-268.
117. Bohmer, R.M. and BURGESS, A.W. (1988) Granulocyte colony stimulating factor (G-CSF) does not induce differentiation of WEHI-3B(D+) cells but is required for the survival of the mature progeny. *Int. J. Cancer.*, 41:53-58.
118. Cebon, J., Dempsey, P., Fox, R., Kannourakis, G., Bonnem, E., BURGESS, A.W. and Morstyn, G. (1988) Pharmacokinetics of human granulocyte-macrophage colony stimulating factor (hGM-CSF) using a sensitive immunoassay. *Blood*, 72:1340-1347.
119. Hamilton, J.A., Vairo, G., Nicola, N., BURGESS, A.W., Metcalf, D. and Lingelbach, S.R. (1988) Activation and proliferation signals in murine macrophages. Synergistic mitogenic interactions between the hematopoietic growth factors and with phorbol ester for DNA synthesis. *Blood*, 71:1574-1580.
120. BURGESS, A.W. and Morstyn, G. (1988) Hemopoietic growth factors: a review. *Cancer Research*, 48:5624-5637.
121. Malden, L.T., Novak, U. and BURGESS, A.W. (1989) Expression of transforming growth factor alpha and messenger RNA in the normal and neoplastic gastrointestinal tract. *Int. J. Cancer*, 43:380-384.
122. BURGESS, A.W. (1989) Life after LIF? *BioEssays*, 10:166-169.

123. BURGESS, A.W. (1990) Granulocyte macrophage colony stimulating factor (GM-CSF). In: Handbook of Experimental Pharmacology ("Peptide Growth Factors and their Receptors"), Vol. 95(I), Springer-Verlag, Berlin, pp.723-745.
124. BURGESS, A.W., Cebon, J. and Smith, S. (1989) Haemopoietic growth factor control of normal and neoplastic cellular proliferation. *Biochem. Soc. Symposium*, 55:57-68.
125. BURGESS, A.W. (1989) The origins of growth factors: tethelin lost. *Trends in Biochem. Sci.*, 14:117-120.
126. BURGESS, A.W. (1989) Epidermal growth factor and transforming growth factor . *British Medical Bulletin*, 45:401-424.
127. BURGESS, A.W. (1989) Haemopoietic growth factors, receptors and oncogenic transformation. In: *Interleukins and Colony Stimulating Factors (Proceedings of 1988 Behring-Kitasato Prize Scientific Symposium)*. Tada, T. (ed), DMB Japan Publishers, Tokyo. pp.61-74.
128. Böhmer, R.M. and BURGESS, A.W. (1989) An autocrine activity capable of substituting for serum in cell cultures. *Growth Factors*, 1: 347-356.
129. Lieschke, G.J., Maher, D., Cebon, J., O'Connor, M., Green, M., Sheridan, W., Boyd, A., Rallings, M., Bonnem, E., Metcalf, D., BURGESS, A.W., McGrath, K., Fox, R.M. and Morstyn, G. (1989) Effects of bacterially synthesized recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy. *Annals Int. Med.*, 110: 357-364.
130. Cebon, J., Nice, E., Gardner, I., Dempsey, P., Layton, J., Dührsen, U., BURGESS, A.W. and Morstyn, G. (1989) Granulocyte macrophage colony stimulating factor from human lymphocytes: Effect of glycosylation on receptor binding and biological activity. *J. Biol. Chem.*, 265: 4483-4491.
131. Sizeland, A. and BURGESS, A.W. (1989) Growth factors that control cancer cells. *Australian Anaesthesia*.
132. Lang, R. and BURGESS, A.W. Autocrine growth factors and tumorigenic transformation. (1990) *Immunology Today*, 11: 244-249.
133. Dempsey, P.J., Layton, J., Dührsen, U., Nicola, N., Cebon, J., BURGESS, A.W. and Morstyn, G. (1990) Monoclonal antibodies which recognize granulocyte macrophage colony stimulating factor and neutralize its bioactivity in vitro. *Hybridoma*, 9: 545-558.
134. Walker, F., Nice, E., Fabri, L., Moy, F.J., Liu, J-F., Scheraga, H.A. and BURGESS, A.W. (1990) Resistance to receptor-mediated degradation of a murine epidermal growth factor analogue (EGF-Val 47) potentiates its mitogenic activity. *Biochemistry*, 29: 10635-10640

135. Sizeland, A., Bol, S. and BURGESS, A.W. (1991) The action of epidermal growth factor (EGF) is limited to specific phases of the cell cycle in an EGF dependent colonic cell line. *Growth Factors*, 4: 129-143.
136. Sizeland, A.M. and BURGESS, A.W. (1991) The proliferative and morphologic responses of a colon carcinoma cell line (LIM 1215) require the production of two autocrine factors. *Mol. Cell. Biol.*, 11: 4005-4014.
137. Walker, F. and BURGESS, A.W. (1991) Reconstitution of the high affinity epidermal growth factor receptor on cell-free membranes after transmodulation by platelet derived growth factor. *J. Biol. Chem.*, 266: 2746-2752.
138. BURGESS, A.W. and Sizeland, A.M. (1990) Growth factors and the gut. *J. Gastroenterol. Hepatol.*, 5(Suppl.1): 10-21.
139. Montelione, G.T., Wuthrich, BURGESS, A.W., Nice, E.C., Wagner, G. and Scheraga, H.A. (1992) Solution structure of a murine epidermal growth factor: stereospecific assignments and heavy atom coordinates. *Biochem.*, 14:236-249.
140. Heyworth, C.M., Hampson, J., Dexter, T.M., Walker, F., BURGESS, A.W., Kan, O., Cook, N., Vallance, S.J. and Whetton, A.D. (1991) Development of multipotential haemopoietic stem cells to neutrophils is associated with increased expression of receptors for granulocyte macrophage colony-stimulating factor. *Growth Factors*, 5:87-98.
141. Whitehead, R.H., Nice, E.C., Lloyd, C.J., James, R. and BURGESS, A.W. (1990) Detection of colonic growth factors using a human colonic carcinoma cell line (LIM 1215). *Int. J. Cancer*, 46: 858-863.
142. Lieschke, G.J., Maher, D., O'Connor, M., Green, M., Sheridan, W., Rallings, M., Bonnem, E., BURGESS, A.W., McGrath, K., Fox, R.M. and Morstyn, G. (1990) Phase I study of intravenously administered bacterially synthesized granulocyte-macrophage colony-stimulating factor and comparison with subcutaneous administration. *Cancer Res.*, 50: 606-614.
143. Austin, L. and BURGESS, A.W. (1991) Stimulation of myoblast proliferation in culture by leukemia inhibitory factor and other cytokines. *J. Neurol. Sci.*, 101: 193-197.
144. Cebon, J., Nicola, N., Ward, M., Gardner, I., Dempsey, P., Layton, J., Dührsen, U., BURGESS, A.W. and Nice, E. (1990) Granulocyte macrophage colony stimulating factor (hGM-CSF) from human lymphocytes: the effect of glycosylation on receptor binding and biological activity. *J. Biol. Chem.*, 265: 4483-4491.
145. Nice, E., Fabri, L., Whitehead, R.H., James, R., Simpson, R.J. and BURGESS, A.W. (1991) The major colonic cell mitogen extractable from colonic mucosa is an N-

- terminally extended form of basic fibroblast growth factor (bFGF). *J. Biol. Chem.*, 266: 14425-14430.
146. Nice, E., Dempsey, P., Layton, J., Morstyn, G., Cui D-F., Simpson, R.J., Fabri, L. and BURGESS, A.W. (1990) Human granulocyte-macrophage colony-stimulating factor (hGM-CSF): Identification of binding site for a neutralizing antibody. *Growth Factors*, 3: 159-169.
  147. Layton, J.E., Nice, E.C., Dempsey, P.J., Fabri, L.J., Cui, D-f., Simpson, R.J., Morstyn, G. and BURGESS, A.W. (1990) In: *UCLA Symposium on Molecular and Cellular Biology, New Series Vol. 120, Hematopoiesis*. Clark, S.C. and Golde, D.W. (eds) Alan R. Liss, Inc., New York, pp 11-21.
  148. Cebon, J. and BURGESS, A.W. (1991) Glycosylation of human granulocyte-macrophage colony stimulating factor alters receptor binding and biological activity. *Trends in Glycoscience and Glycotechnology*, 3:266-274.
  149. Layton, J.E., Morstyn, G., Fabri, L.J., Reid, G.E., BURGESS, A.W., Simpson, R.J. and Nice, E.C. (1991) Identification of a functional domain of human granulocyte colony-stimulating factor using neutralizing monoclonal antibodies. *J. Biol. Chem.*, 266:23815-23823.
  150. Nice, E.C., Fabri, L., Hammacher, A., Holden, J., Maruta, H., Simpson R. J. and BURGESS, A.W. (1992) The purification of a rap1 GTP'ase activating protein from bovine brain cytosol. *J. Biol. Chem.*, 267:1546-1553.
  151. Montelione, G.T, Wüthrich, K., BURGESS, A.W., Nice, E.C., Wagner, G., Gibson, K.D., and Scheraga, H.A. (1992) Solution structure of murine epidermal growth factor determined by NMR spectroscopy and refined by energy minimization with restraints. *Biochemistry*, 31:236-249.
  152. Maruta, H., BURGESS, A.W. (1992) Ras - A common cancerous gene. *Today's Life Science*, 4(8):24-32.
  153. BURGESS, A.W. Turner, D.R. (1992) The Oncogenes. In: *Communication With in Animal Cells*. G. J. Barritt (ed). Oxford, Oxford University Press, pp. 291-314
  154. BURGESS, A.W. (1992) Cooperative Research Centre: Cellular Growth Factors. *Australian Biotechnology*, 2(4):207-209
  155. Sizeland, A.M., BURGESS, A.W. (1992) Anti-sense TGF oligonucleotides inhibit autocrine stimulated proliferation of a colon carcinoma cell line. *Molec. Biol. Cell*, 3:1235-1243.
  156. Fabri, L., Nice, E.C., Ward, L.D., Maruta, H., BURGESS, A.W., Simpson, R.J. (1992) Characterization of bovine heparin-binding neurotrophic factor (HBNF): assignment of disulphide bonds. *Biochem.International*, 28:1-9.

157. BURGESS, A.W. Growth Factors, Oncogenes and Gastrointestinal Cancers. Proceedings of 1992 Shanghai International Symposium on Gastroenterology. Shao-ji Jiang and Shu-dong Xiao (eds.) Shanghai, Shanghai Scientific & Technical Literature Publishers, pp 17-28.
158. Walker, F., deBlaquiere, J. and BURGESS, A.W. (1993) Translocation of pp60c-src from the plasma membrane to the cytosol after stimulation by platelet-derived growth factor. *J.Biol.Chem.*, 268:19552-19558.
159. Nice, E., Layton, J., Fabri, L., Hellman, U., Engstrom, A., Persson, B. and BURGESS, A.W. (1993) Mapping of the antibody and receptor binding domains of G-CSF using an optical biosensor: comparison with ELISA competition studies. *J.Chrom.*, 646:159-168.
160. Fabri, L., Maruta, H., Muramatsu, H., Muramatsu, T., Simpson, R.J., BURGESS, A.W. and Nice, E.C. (1993) Structural characterisation of native and recombinant forms of the neurotrophic cytokine MK. *J. Chrom.*, 646:213-225.
161. Hong, J., Baldwin, G.S., BURGESS, A.W., Moritz, R.L., Ward, L.D. and Simpson, R.J. (1993) EGF induces serine phosphorylation of stathmin in a human carcinoma cell line. *J.Biol.Chem.*, 268:13396-13405.
162. deBlaquiere, J., Walker, F., Michelangeli, V.P., Fabri, L. and BURGESS, A.W. (1994) Platelet-derived growth factor stimulates the release of protein kinase A from the cell membrane. *J.Biol.Chem.*, 269:4812-4818.
163. Maruta, H., Bartlett, P.F., Nurcombe, V., Nur-E-Kamal, M.S.A., Chomienne, C., Muramatsu, T., Muramatsu, H., Fabri, L., Nice, E. and BURGESS, A.W. (1993) Midkine (MK), a retinoic acid (RA)-inducible gene product, produced in *E.coli* acts on neuronal and ML60 leukemia cells. *Growth Factors*, 8:119-134.
164. Nice, E., Lackmann, M., Smyth, F., Fabri, L. and BURGESS, A.W. (1994) Synergies between micropreparative HPLC and an instrumental optical biosensor. *J.Chrom.*, 660:169-185.
165. Walker, F. and BURGESS, A.W. (1995) Epidermal Growth Factor Receptors. In: *Guidebook to Cytokines and their Receptors*. Ed. N. Nicola. Oxford University Press. pp198-201.
166. BURGESS, A.W. (1994) Designing amino acids to determine the local conformations of peptides. *PNAS USA*, 91:2649-2653.
167. BURGESS, A.W. (1995) Polyfunctionality of haemopoietic regulators: The Metcalf Forum. *Growth Factors*, 12(1):85-86.
168. Dunn, A.R., Mann, G.B., Fowler, K., Grail, D., Hibbs, M., Alexander, W., Walker, F. and BURGESS, A.W. Insights into the physiology of TGF and signalling through the EGF receptor revealed by gene targeting and acts of nature. *The 24th International*

Symposium of The Princess Takamatsu Cancer Research Fund. Princeton Scientific Publishing Co., Inc. 24: 276-289, 1994.

169. BURGESS, A.W. Growth Factors and Cancer Treatment. (1994) *Ciencia e Cultura*, 46:13-17.
170. Maruta, H. and BURGESS, A.W. (1994) Regulation of the ras signalling network. *BioEssays*, 16(7):489-496.
171. BURGESS, A.W. and Thumwood, C M. (1994) Growth factors and their receptors: new opportunities for cancer treatment. The Sixth George Swanson Christie Memorial Lecture. *J.Pathol.*, 26:453-463.
172. BURGESS, A.W. (1995) Growth Factors. In *Molecular Biology and Biotechnology: A Comprehensive Desk Reference* (Ed. Robert A. Meyers) VCH Publishers Inc., New York. pp. 392-397.
173. BURGESS, A.W. (1994) Hemopoietic growth factor control of normal cell production. In *Principles of Molecular Biology* (E & N Bittar, eds.) JAI Press, Greenwich.
174. Rosenthal, M.A. and BURGESS, A.W. (1994) A brave new world of cancer screening. *A.N.Z. J. Med.*, 24:677-678.
175. Groenen, L.C., Nice, E.C. and BURGESS, A.W. (1994) Structure-function relationships for the EGF/TGF- family of mitogens. *Growth Factors*, 11:235-257.
176. Zhang, Q-X, Baldwin, G.S., Walker, F. and BURGESS, A.W. (1994) Reduction in platelet-derived growth factor receptor mRNA in v-SCR-transformed fibroblasts. *Biochemica et Biophysica Acta*, 1266:9-15.
177. Fowler K.J., Walker, F., Alexander, W., Hibbs, M.L., Nice, E.C., Bohmer, R.M, Mann, G.B., Thumwood, C., Maglitto, R., Danks, J.A., Chetty, R., BURGESS, A.W. and Dunn A.R. (1995) A mutation in the epidermal growth factor receptor in waved-2 mice has a profound effect on receptor biochemistry that results in impaired lactation. *PNAS*, 92:1465-1469.
178. Davis I.D., Treutlein H. R., Friedrich K. and BURGESS, A.W. (1995) A potent human interleukin-4 antagonist stimulates the proliferation of murine cells expressing the human interleukin-4 binding chain. *Growth Factors*, 12:69-83.
179. O'Donohue M.F., BURGESS A.W., Walkinshaw, M.D. and Treutlein, H.R. (1995) Modelling conformational changes in Cyclosporin A. *Protein Science*, 4:2191-2202.
180. Nice E., Smyth F., Domagala T., Fabri L., Catimel B. and BURGESS, A.W. (1995) Exploiting synergies between micropreparative HPLC and BIA. *BIAjournal*, 3:14-15.

181. BURGESS A.W. (1995) Growth Factors. In Molecular Biology Encyclopedia: Fundamentals and Applications. Pp. 463-471. Ed. Robert A. Meyers. VCH Publishers, Inc., New York.
182. D'Abaco, G. M., BURGESS A.W. and Whitehead, R.H. (1996) Synergy between  $Apc^{min}$  and an activated *ras* mutation is sufficient to induce colon carcinomas. Mol. Cell. Biol., 16(3):884-891.
183. Hair, G.A., Padula, S., Zeff, R., Schmeizl, M., Contrino, J., Kreutzer, D., de Moerloose, P., Boyd, A.W., Stanley, I., BURGESS, A. W. and Rickles, F. R. (1996) Tissue factor expression in human leukemic cells. Leuk. Res., 20(1):1-11.
184. BURGESS, A.W. and Tran Trung Tran (1996). GroCyt Database. Chapman & Hall, Melbourne.
185. Nice E., Smyth F., Domagala T., Fabri L., Catimel B. and BURGESS, A. W. (1996). Synergies between micropreparative HPLC and an optical biosensor: Applications to structure/function studies. Science Tools, 1(3):3-5.
186. Catimel, B., Ritter, G., Welt, S., Old, L.J., Cohen, L., Nerrie, M.A., White, S.J., Heath, J.K., Demediuk, B., Domagala, T., Lee, F.T., Scott, A.M., Tu, G.F., Ji, H., Moritz, R.L., Simpson, R.J., BURGESS, A.W. and Nice, E.C. (1996). Purification and characterization of a novel restricted antigen expressed by normal and transformed human colonic epithelium. J. Biol. Chem., 271(41):25664-25670.
187. BURGESS, A.W. (1996). Mammals I: Regulation of RAS Activation. In Regulation of the RAS Signalling Network. Molecular Biology Intelligence Unit, R G Landes Company, Austin, Texas. Eds. H. Maruta and A. W. Burgess. pp. 75-94. Springer.
189. Groenen, L.C., Walker F., BURGESS, A.W. and Treutlein, H.R. (1997). A model for the activation of the epidermal growth factor receptor kinase: involvement of an asymmetric dimer? Biochemistry, 36(13):3826-3836.
190. Ji, H., Moritz, R.L., Reid, G.E., Ritter, G., Catimel, B., Nice, E., Heath, J.K., White, S.J., Old, L.J., BURGESS, A.W. and Simpson, R.J. (1997). Electrophoretic analysis of the novel antigen for the gastrointestinal-specific monoclonal antibody, A33. Electrophoresis, 18:614-621.
191. Heath, J.K., White, S.J., Johnstone, C.N., Catimel, B., Simpson, R.J., Moritz, R.J., Tu, G-F., Whitehead, R.J., Groenen, L.C., Scott, A.M., Ritter, G., Cohen, L., Welt, S., Old, L.J., Nice, E.C. and BURGESS, A.W. (1997). The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily. PNAS USA, 94:469-474.
192. Nice, E., Catimel, B., Lackmann, M., Stacker, S., Runting, A., Wilks, A., Nicola, N. and BURGESS, A.W. Strategies for the identification and purification of ligands for orphan biomolecules. (1997) Letter in Peptide Science 4: 107-120.

193. Ji, H., Reid, G.E., Moritz, R.L., Eddes, J.S., BURGESS, A.W. and Simpson, R.J. (1997) A two-dimensional gel database of human colon carcinoma proteins. *Electrophoresis*, 18:605-613.
194. Catimel, B., Nerrie, M., Lee, F-T., Scott, A.M., Ritter, G., Welt, S., Old, L.J., BURGESS, A.W. and Nice, E.C. (1997). Kinetic analysis of the interaction between the monoclonal antibody A33 and its colonic epithelial antigen using an optical biosensor: A comparison of immobilisation strategies. *J. Chromatogr.*, 776:15-30.
195. Moritz, R.L., Ritter, G., Catimel, B., Cohen, L.S., Welt, S., Old, L.J., BURGESS, A.W., Nice, E.C. and Simpson, R.J. (1998). Micro-sequencing strategies for the human A33 antigen, a novel surface glycoprotein of human gastrointestinal epithelium. *J.Chromatogr.*, 798:91-101.
196. Catimel, B., Scott, A.M., Lee, F.T., Hanai, N., Ritter, G., Welt, S., Old, L.J., BURGESS, A.W. and Nice, E.C. (1998). Direct immobilisation of gangliosides onto gold-carboxymethyldextran sensor surfaces by hydrophobic interaction: Applications to antibody characterisation. *Glycobiol.*, 8:927-938.
197. Walker, F., Hibbs, M.L., Zhang, H.H., Gonez, L.J. and BURGESS, A.W. (1998) Biochemical characterization of mutant EGF receptors expressed in the hemopoietic cell line BaF/3. *Growth Factors*, 16(1) 53-67.
198. Walker, F., Kato, A., Gonez, J., Hibbs, M.L., Pouliot, N., Levitzki, A. and BURGESS, A.W. (1998) Activation of the Ras/MAPK pathway by kinase defective epidermal growth factor receptors results in cell survival but not proliferation. *Mol. Cell. Biol.*, 18:7192-7204.
199. Zugaro, L.M., Reid, G.E., Ji, H., Eddes, J.S., Murphy, A.C., BURGESS, A.W., and Simpson, R.J. (1998). Characterization of rat brain stathmin isoforms by two-dimensional gel electrophoresis-matrix assisted laser desorption/ionization and electrospray ionization-ion trap mass spectrometry. *Electrophoresis*, 19:867-876.
200. de Blaquiére, J. and BURGESS, A.W. (1999) Affinity purification of cell surface membranes with functional epidermal growth factor receptors. *J. Bio. Tech.*, 10:64-71.
201. O'Donohue, M.F., Minasian, E., Leach, S.J., BURGESS, A.W., & Treutlein, H.R. (2000). PEPCAT – A new tool for conformational analysis of peptides. *Journal of Comparative Chemistry*, 21:446-461
202. Domagala, T., Konstantopoulos, N., Smyth, F., Jorissen, R.N., Fabri, L., Geleick, D., Lax, I., Schlessinger, J., Schlessinger, J., Sawyer, W., Howlett, G.J., BURGESS, A.W. & Nice, E.C. (2000). Stoichiometry, kinetic & binding analysis of the interaction between epidermal growth factor (EGF) & the extracellular domain of the EGF receptor. *Growth Factors*, 18:11-29

203. Jorissen, R.N., Epa, V.C., Treutlein, H.R., Garrett, T.P.J., Ward, C.W. & BURGESS, A.W. (2000). Characterization of a Comparative Model of the Extracellular Domain of the Epidermal Growth Factor Receptor. *Protein Science*, 9:310-324
204. Johnstone, C.N., Tebbutt, N.C., Abud, H.E., White, S.J., Stenvers, K.L., Hall, N.E., Cody, S.H., Whitehead, R.H., Catimel, B., Nice, E.C., BURGESS, A.W. & Heath, J.K. (1999). Characterization of mouse A33 antigen; a definitive marker for basolateral surfaces of intestinal epithelial cells. *American Journal of Physiology*, 279:G500-G510.
205. Chen, H-S., Cai, S-L., Wang, Y., Zhao, H-T., Peng, J-R., Pang, X-W., Zhu, J-Y., Cong, X., Rui, J-A., Leng, X-S., Du, R-Y., Wang, Y., Vaughan, H., Cebon, J., BURGESS, A.W. & Chen, W-F. (2000). Expression of MAGE-1 gene in human hepatocellular carcinomas. *The National Medical Journal of China*, 113: 1112-1118
206. Scott, A.M., Geleick, D., Rubira, M., Clarke, K., Nice, E.C., Smyth, F.E., Stockert, E., Richards, E.C., Carr, F.J., Harris, W.J., Armour, K.L., Rood, J., Kypridis, A., Kronina, V., Murphy, R., Lee, F-T., Liu, Z., Kitamura, K., Ritter, G., Laughton, K., Hoffman, E., BURGESS, A.W. & Old, L.J. (2000). Construction, production and characterization of humanized anti-lewis<sup>y</sup> monoclonal antibody 3S193 for targeted immunotherapy of solid tumors. *Cancer Research*, 60:3254-3262
207. Pouliot, N. & BURGESS, A.W. (1999). Multiple autocrine factors including an extracellular matrix protein are required for the proliferation and spreading of human colon carcinoma cells *in vitro*. *Growth Factors*, 18:31-49
208. Fridman, M., Maruta, H., Gonez, J., Walker, F., Treutlein, H., Zeng, J. & BURGESS, A.W. (2000). Point mutants of cRaf-1 RBD with elevated binding to v-H-Ras. *J. Biol. Chem.*, 275:30363-30371.
209. Fridman, M., Walker, F., Catimel, B., Domagala, T., Nice, E. & BURGESS, A.W. (2000). c-Raf-1 RBD associates with a subset of active v-H-Ras. *Biochemistry*, 39:15603-15611.
210. Akbarzadeh, S., McPhee, D., Alexander, W.S., Lieschke, G., Layton, J.E., & BURGESS, A.W. (2000) G-CSF receptor tyrosines are involved in signal transduction in normal haemopoietic cells. *Experimental Hematology*. 28(7): 39-39.
211. Lee, F-T., Rigopoulos, A., Hall, C., Clarke, K., Cody, S.H., Smyth, F.E., Liu, Z., Brechbiel, M.W., Hanai, N., Nice, E., Catimel, B., BURGESS, A.W., Welt, S., Ritter, G., Old, L. & Scott, A. (2001). Specific localisation, gamma camera imaging and intracellular trafficking of radiolabelled chimeric anti-GD3 ganglioside monoclonal antibody KM871 in SK-Mel-28 melanoma xenografts. *Cancer Research*, 61:4474-82
212. Lee, F.T., Hall, C., Rigopolous, A., Zweit, J., Pathmaraj, K., Hannah, A., O'Keefe, G., Chan, J., Pharm, B., Smyth, F.E., Welt, S., Old, L.J., BURGESS, A.W. & Scott, A.M. (2001). Immuno-pet of human colon xenograft- bearing balb/c nude mice using (124) I-cdr-grafted humanized a33 monoclonal antibody. *J Nucl Med.*, 42: 764-769.

213. Pouliot, N., Connolly, L.M., Moritz, R.L., Simpson, R.J. & BURGESS, A.W. (2000). Colon cancer cells adhesion and spreading on autocrine laminin-10 is mediated by multiple integrin receptors and modulated by EGF receptor stimulation. *Experimental Cell Research*, 261:360-371.
214. Tran, T.T., Treutlein, H. & BURGESS, A.W. (2001). Conformational Analysis of Thiopeptides: Derivation of SP<sup>2</sup> Sulfur Parameters for the CFF91 Force Field. *The Journal of Computational Chemistry*, 22:1010-1025
215. Luwor R.B. , Johns T.G., Munrone C., Huang H.J.S., Cavanee W.K., Ritter G., Old L.J., BURGESS A.W. and Scott A.M. (2001) Monoclonal antibody 806 inhibits the growth of tumour xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR. *Cancer Res.* 61:5355-61
216. He H., Levitzki A., Zhu H-J., Walker F., BURGESS A.W., and Maruta H. (2001). Platelet-derived growth factor requires epidermal growth factor receptor to activate p21-activated kinase family kinases. *J. Biol. Chem.* 276: 26741-44.
217. Tran, T.T., Treutlein, H. & BURGESS, A.W. (2001). Conformational Analysis of Thiopeptides: ( $\phi, \psi$ ) maps of thio substituted dipeptides. *The Journal of Computational Chemistry*, 22:1026-1037
218. Pouliot, N., Nice, E.C. & BURGESS, A.W. (2001). Laminin-10 mediates basal and EGF-stimulated motility of human colon carcinoma cells via  $\alpha_3\beta_1$  and  $\alpha_6\beta_4$  integrins. *Experimental Cell Research*, 266(1):1-10
219. Zeng, J., Nheu, T., Zorzett, A., Catimel, B., Nice, E., Martuta, H., BURGESS, A.W. & Treutlein, H. (2001). Design of inhibitors of Ras-Raf interaction using a computational combinatorial algorithm. *Protein Engineering*, 14:39-45.
220. Elleman, T.C., Domagala, T., McKern, N.M., Nerrie, M., Lönnqvist, B., Adams, T.E., Lovrecz, G.O., Hoyne, P.A., Richards, K.M., Howlett, G.J., Rothacker, J., Jorissen, R.N., Lou, M., Garret, T.P.J., BURGESS, A.W., Nice, E.C. & Ward, C.W. (2001). Characterisation of a truncated, high affinity form of the epidermal growth factor receptor ectodomain and identification of a determinant of ligand binding specificity. *Biochemistry*. 40: 8930-39.
221. Nagane M., Narita Y., Mishima K., Levitzki A., BURGESS A.W., Cavanee W.K., and Huang H.J.S. (2001) Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor. *J. Neurosurg.* 95: 472-79.
222. Scott A.M., Lee F.T., Hopkins W., Cebon J.S., Wheatley J.M., Liu Z., Smyth F.E., Murone C., Sturrocks S., MacGregor D., Hanai N., Inoue K., Yamasaki M., Brechbiel M.W., Davis I.D., Murphy R., Hannah A., Lim-Joon M., Chan T., Ritter G., Hoffman E.W., BURGESS A.W., and Old L.J. (2001). Specific Targeting, Biodistribution, and Lack of Immunogenicity of Chimeric Anti-GD3 Monoclonal Antibody KM871 in

- Patients With Metastatic Melanoma: Results of a Phase 1 Trial. *J. Clin. Oncol.* 19: 3976-87.
223. Ellis, A.G., Nice, E.C., Weinstock, J., Levitzki, A., BURGESS, A.W. & Webster, L.K. (2001). High performance liquid chromatographic analysis of the tyrphostin AG1478, a specific inhibitor of epidermal growth factor receptor tyrosine kinase, in mouse plasma. *J. Chrom.*, 754:193-199.
224. Tran, T.T., BURGESS, A.W., Treutlein, H. & Perich, J. (2001). Synthesis, X-ray crystallographic structures of thio substituted *N*-acetyl *N'*-methylanide alanine and evaluation of  $sp^2$  sulfur parameters of the CFF91 force field. *J. Pept. Res.*, 58:67-78.
225. Wade, J.D., Catimel, B., Faux, M.C., BURGESS, A.W., Nice, E.C., and Otvos, L. (2001) Structural and biosensor analyses of a synthetic biotinylated peptide probe for the isolation of adenomatous polyposis coli tumor suppressor protein complexes. *J. Pept. Res.* 58:204-12.
226. Tran, T.T., BURGESS, A.W., Treutlein, H. & Perich, J. (2001). Synthesis, X-ray crystallographic structures of thio substituted *N*-acetyl *N'*-methylanide alanine and evaluation of  $sp^2$  sulfur parameters of the CFF91 force field. *J. Pept. Res.*, 58:67-78.
227. Catimel, B., Faux, M.C., Nerrie, M., Rothacker, Otvos, L., Wade, J.D., Nice, E.C., & BURGESS, A.W. (2001) The use of coiled-coil interactions for the analysis and micropreparative isolation of adenomatous polyposis coli protein complexes. *Journal of Peptide Research.* 58(6): 493-503.
228. Tran, T.T., BURGESS, A.W., Treutlein, H., & Zeng, J. (2001) Conformational analysis of thiopeptides: free energy calculations on the effects of thio-substitutions on the conformational distributions of alanine dipeptides. *Journal of Molecular Graphics & Modelling.* 20(3): 245-256.
229. Johns, T.G., Stockert, E., Ritter, G., Jungbluth, A.A., Su Huang, H-J., Cavenee, W.K., Smyth, F.E., Hall, C.M., Watson, N., Nice, E.C., Gullick, W.J., Old, L.J., BURGESS, A.W. & Scott, A.M. (2002). A Novel Monoclonal antibody specific for the DE2-7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene. *Int. Journal of Cancer.* 98(3):398-408.
230. BURGESS, A.W. Tyr kinase inhibitors as potential anticancer agents: EGF receptor and ABL kinases. (2002) In, *Tumour-suppressing viruses, genes, and drugs: innovative cancer therapy approaches.* 341-359. San Diego, Publisher: Academic Press, Editors: Maruta, H.
231. Wang, Y., Han, K-J., Pang, X-W., Vaughan, H.A., Qu, W., Dong, X-Y., Peng, J-R., Zhao, H-T., Rui, J-A., Leng, X-S., Cebon, J., BURGESS, A.W., & Chen, W-F. (2002) Large Scale Identification of Human Hepatocellular Carcinoma-Associated Antigens by Autoantibodies. *The Journal of Immunology.* 169:1102-1109.

232. Garrett, T.P.J., McKern, N.M., Lou, M., Elleman, T.C., Adams, T.E., Lovrecz, G.O., Zhu, H-J., Walker, F., Frenkel, M.J., Hoyne, P.A., Jorissen, R.N., Nice, E.C., BURGESS, A.W., & Ward, C.W. (2002) Crystal Structure of a Truncated Epidermal Growth Factor Receptor Extracellular Domain Bound to Transforming Growth Factor  $\alpha$ . *Cell*. 110:763-773
233. Liu, Z., Lee, F-T., Hanai, N., Smyth, F.E., BURGESS, A.W., Old, L.J., & Scott, A.M. (2002) Cytokine Enhancement of *in vitro* Antibody-Dependent Cellular Cytotoxicity Mediated by Chimeric anti-GD3 Monoclonal Antibody KM871. *Cancer Immunity*. 2:13.
234. Nheu, T.V., He, H., Hirokawa, Y., Tamaki, K., Florin, L., Schmitz, M.L., Suzuki-Takahashi, I., Jorissen, R.N., BURGESS, A.W., Nishimura, S., Wood, J., & Maruta, H. (2002) The K252a derivatives, inhibitors for the PAK/MLK kinase family, selectively block the growth of RAS transformants. *Cancer Journal* 8(4): 328-336.
235. Nice, E.C., Domagala, T., Fabri, L., Nerrie, M., Walker, F., Jorissen, R.N., BURGESS, A.W., Cui, D.F., & Zhang, Y.S. (2002) Rapid microscale enzymic semisynthesis of Epidermal Growth Factor (EGF) analogues. *Growth Factors*. 20(2): 71-80.
236. Jorissen, R.N., Treutlein, H.R., Epa, V.C., & BURGESS, A.W. (2002) Modeling the epidermal growth factor – epidermal growth factor receptor 12 domain interaction: implications for the ligand binding process. *J. Biol. Struct. Dyn.* 19(6): 961-72.
237. BURGESS A.W., Cho H.S., Eigenbrot C., Ferguson K.M., Garrett T.P., Leahy D.J., Lemmon M.A., Sliwkowski M.X., Ward C.W., Yokoyama S. (2003). An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. *Mol Cell*. 12(3):541-52.
238. Garrett, T.P.J., McKern, N.M., Lou, M., Elleman, T.C., Adams, T.E., Lovrecz, G.O., Kofler, M., Jorissen, R.N., Nice, E.C., BURGESS, A.W., & Ward, C.W. (2003). The first 3 domains of ErbB2 ectodomain adopt a pseudo-active form of the receptor. *Molecular Cell*. 11:495-505.
239. Zhu, H-J., Iaria, J., Orchard, S., Walker, F., & BURGESS, A.W. (2003) Epidermal Growth Factor Receptor: Association of Extracellular Domain Negatively Regulates Intracellular Kinase Activation in the Absence of Ligand. *Growth Factors*. 21(1):15-30.
240. Johns T.G., Luwor, R.B., Munrone, C., Walker, F., Weinstock, J., Vitali, A.A., Perera, R.M., Jungbluth, A.A., Stockert, E., Old, L.J., Nice, E.C., BURGESS, A.W., & Scott, A.M. (2003) Antitumour efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478. *PNAS*. 100(26) 15871-15876.
241. Faux, M.C., Ross, J.L., Meeker, C., Johns, T., Ji, Hong, Simpson, R.J., Layton, M.J. & BURGESS, A.W. (2004) Restoration of full-length adenomatous polyposis coli

- (APC) protein in a colon cancer cell line enhances cell adhesion. *Journal of Cell Science* 117:427-439.
242. Walker, F., Orchard, S.G., Jorissen, R.N., Hall, N.E., Zhang, H.H., Hoyne, P.A., Adams, T.E., Johns, T.G., Ward, C., Garrett, T.P., Zhu, H.J., Nerrie, M., Scott, A.M., Nice, E.C., & BURGESS, A.W. (2004) CR1/CR2 interactions modulate the functions of the cell surface epidermal growth factor receptor. *J. Biol. Chem.* 279 (21): 22387-98.
243. Luwor, R.B., Zhu, H.J., Walker, F., Vitali, A.A., Perera, R.M., BURGESS, A.W., Scott, A.M. & Johns, T.G. (2004) The tumor-specific de2-7 epidermal growth factor receptor (EGFR) promotes cells survival and hereodimerizes with the wild-type EGFR. *Oncogene*. 23(36): 6095-104.
244. Johns T.G., Adams T.E., Cochran J.R., Hall N.E., Hoyne P.A., Rothacker J., Richards K.M., Kim Y.S., Nice E.C., Walker F., Ritter G., Jungbluth A.A., Old L.J., Ward C.W., BURGESS A.W., Wittrup K.D., and Scott A.M. (2004) Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor. *Journal of Biological Chemistry*. 279 (29): 30375-84
245. Lee F-T., Mountain A.J., Kelly M.P., Hall C, Rigopoulos A., Johns T.G., Smyth F.E., Brechbiel M.W., Nice E.C., BURGESS A.W., and Scott A.M. Enhanced Efficacy of Radioimmunotherapy with 90Y-CHX-A"-DTPA-hu3S193 by Inhibition of Epidermal Growth Factor Receptor (EGFR) Signaling with EGFR Tyrosine Kinase Inhibitor AG1478. *Clinical Cancer Research*. 11 (19 Pt2): 7080s-7086s (2005)
246. Catimel B., Rothacker J., Catimel J, Faux M.C., Ross J.L., Connolly L., Clippingdale A.B., BURGESS A.W., and Nice E. Biosensor-Based Micro-Affinity Purification for the Proteomic Analysis of Protein Complexes. *Journal of Proteome Research*. 4 (5): 1646-1656(2005)
247. Perera R.M., Narita Y., Furnari F.B., Gan H., Murone C., Ahlqvist M., Luwor R.B., BURGESS A.W., Stockert E., Jungbluth A.A., Old L.J., Tamaki K., Scott A.M., and Johns T.G. Treatment of Human Tumor Xenografts with Monoclonal Antibody 806 in Combination with a Prototypical Epidermal Growth Factor Receptor-Specific Antibody Generates Enhanced Antitumor Activity. *Clinical Cancer Research*. 11 (17): 6390-6399 (2005)
248. Alewood D., Nielsen K, Alewood P.F., Craik D.J, Andrews P, Nerrie M., White S., Domagala T., Rothacker J., BURGESS A.W., and Nice E.C. The role of disulfide bonds in the structure and function of murine epidermal growth factor (mEGF). *Growth Factors*. 23 (2): 97-110 (2005)
249. Chong G., Lee F-T., Hopkins W., Tebbutt N.C., Cebon J.S., Mountain A., Chappell B, Papenfuss A., Schleyer P, U P.L., Murphy R., Wirth V, Smyth F., Potasz N, Poon A.,

- Davis I.D., Saunderson T, O'Keefe GJ, BURGESS A.W., Hoffman E.W., Old L.J., and Scott A.M. Phase I Trial of 131I-huA33 in Patients with Advanced Colorectal Carcinoma. *Clinical Cancer Research*. 11 (13): 4818-26 (2005)
250. Scott A.M., Lee F-T., Jones R, Hopkins W., MacGregor D., Cebon J.S., Hannah A., Chong G., U P.L., Rigopoulos A., Sturrock S., Murphy R., Wirth V, Murone C., Smyth F.E., Knight S., Welt S., Ritter G., Richards E., Nice E.C., BURGESS A.W., and Old L.J. A Phase I Trial of Humanized Monoclonal Antibody A33 in Patients with Colorectal Carcinoma: Biodistribution, Pharmacokinetics, and Quantitative Tumor Uptake. *Clinical Cancer Research*. 11 (13): 4810-17 (2005)
  251. Clayton A.H., Walker F., Orchard S.G., Henderson C, Fuchs D, Rothacker J., Nice E.C., and BURGESS A.W. Ligand induced dimer-tetramer transition during the activation of the cell surface epidermal growth factor receptor-A multidimensional microscopy analysis. *Journal of Biological Chemistry*. 280 (34): 30392 - 30399 (2005)
  252. Clayton A.H., Perugini M.A., Weinstock J., Rothacker J., Watson K.G., BURGESS A.W., and Nice E.C. Fluorescence and analytical ultracentrifugation analyses of the interaction of the tyrosine kinase inhibitor, tyrphostin AG1478-mesylate, with albumin. *Analytical Biochemistry*. 342 (2): 292-9 (2005)
  253. Panousis C, Rayzman V.M., Johns T.G., Renner C., Liu Z., Cartwright G., Lee F-T., Wang D., Gan H., Cao D., Kypridis A., Smyth F.E., Brechbiel M.W., BURGESS A.W., Old L.J., and Scott A.M. Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR. *British Journal of Cancer*. 92 (6): 1069-77 (2005)
  254. Johns T.G., Mellman I., Cartwright G.A., Ritter G., Old L.J., BURGESS A.W., and Scott A.M. The antitumor monoclonal antibody 806 recognizes a high-mannose form of the EGF receptor that reaches the cell surface when cells over-express the receptor. *FASEB Journal*. 19 (7): 780-2 (2005)

## Reviews

1. Lieschke, G.J., BURGESS, A.W. (1992) Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. *N. Eng. J. Med.*, 327:28-35 & 99-106.
2. Groenen, L.C., Nice, E.C. and BURGESS, A.W. (1994) Structure-function relationships for the EGF/TGF- family of mitogens. *Growth Factors*, 11:235-257
3. Zhu, H. & BURGESS, A.W. (2001). Regulation of Transforming Growth Factor- $\beta$  Signaling. *Mol. Cell Biol. Res. Comm.*, 4:321-30
4. Jorissen, R.N., Walker, F., Pouliot, N., Garrett, T.P.J., Ward, C.W., & BURGESS, A.W. (2003) Epidermal Growth Factor Receptor: Mechanisms of Activation and Signalling. *Experimental Cell Research* 284: 31-53
5. Burgess AW, Cho HS, Eigenbrot C, Ferguson KM, Garrett TP, Leahy DJ, Lemmon

MA, Sliwkowski MX, Ward CW, Yokoyama S. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. *Mol Cell*. (2003) Sept;12(3):541-52.

### **Encyclopedia Articles**

1. BURGESS, A.W. "Growth Factors". In: *Encyclopedia of Molecular Biology and Molecular Medicine*. Ed. Robert A. Meyers. Weinham (Germany); New York: VCH, 2003
2. BURGESS, A.W. "Epidermal Growth Factors". In: *Encyclopedia of Hormones*. Eds: Helen Henry & Anthony Norman. Academic Press 2003

### **Research Books**

1. *Growth Factors and Stem Cells*. A.W. BURGESS & N. Nicola. Academic Press 1983
2. *Growth factors and their receptors: genetic control and rational application: proceedings of an Abbott-Cetus-Genetech-Smith, Kline & French-UCLA Symposium held in Keystone, Colorado, January 24-30, 1988*. Editors: Russell Ross, ANTONY W. BURGESS, Tony Hunter. New York: Liss 1989
3. *Regulation of the RAS Signaling Network*. Editors: Hiroshi Maruta and ANTONY W. BURGESS. R.G., Landes Company, Austin. Springer 1996

### **Book Chapters**

1. BURGESS, A.W. Cytokine/Growth factor Responsiveness of early Hemopoietic Progenitor Cells. In: Eds. Peter J Quesenberry, Gary W Stein, Bernard Forget, Sherman Weissman "Stem Cell Biology and Gene Therapy", Wiley-Liss, Inc. New York, pp15-39.
2. BURGESS, A.W. Tyr Kinase Inhibitors as Potential Anticancer Agents: EGF Receptor and ABL Kinases. In: Ed. Hiroshi Maruta "Tumor-Suppressing Viruses, Genes, and Drugs", Academic Press, pp341-359.
3. BURGESS, A.W. Mammals I: Regulation of RAS Activation. In Eds. Hiroshi Maruta, Antony W. Burgess "Regulation of the RAS Signaling Network". Springer, pp75-94.

### **Databases**

1. Cancer Research Australia (CARA) <http://www.ludwig.edu.au/cara2/index2.html>
2. BURGESS, A.W. & Tran, T.T. *Growth Factors and Cytokines (GroCyt)*. Publishers: Chapman & Hall

## **12. PATENTS**

**Method of Influencing Kinase Activity**

Appl<sup>n</sup>s: WO Application Serial Number 10,074,871; 12 Feb 2003

**Chimerized Cytokine Antibody**

Appl<sup>n</sup>s: US Application Serial Number 60/355,838; 13 Feb 2002

**Crystal structure of erbB2**

Appl<sup>n</sup>s: Australian Prov 2002951853

**Methods of screening based on EGF R crystal structure**

Appl<sup>n</sup>s: (AU) PR6827, PR6828, PS 2731; (USA) 60/335393, 60/336560 & 60/388171  
WO 03014159

**Anti-EGFR antibody**

Appl<sup>n</sup>s: WO 200292771

**Truncated epidermal growth factor receptor**

Appl<sup>n</sup>s: WO 200200876; AU 200167156; EP 1200581

**EGFR Model**

Appl<sup>n</sup>s: WO 9962955; EP 1082345; JP 2002517408  
Granted: AU 753488

**A33 Antigen**

Appl<sup>n</sup>s: WO 9708189; EP 85187; JP 11511973  
Granted: US 5712369; AU 701105; US 6291235

**POMC(76-103) Growth Factor**

Appl<sup>n</sup>s: WO 9523214; EP 785990; JP 9509573  
Granted: US 5547940; AU 689560